Tu canal independiente de oncología en español
Regístrate aquí para recibir más contenidos
Registrarse
OncoBites te trae los resúmenes y
presentaciones más relevantes del congreso
ESMO 2025
Top resúmenes y presentaciones
Ensartinib as adjuvant therapy in patients (pts) with
stage IB–IIIB ALK-positive (ALK+) non-small cell lung
cancer (NSCLC) after complete tumor resection: the
phase III randomized ELEVATE trial
LBA66
Updated results from the phase III ALINA study of adjuvant
alectinib vs chemotherapy (chemo) in patients (pts) with
early-stage ALK+ non-small cell lung cancer (NSCLC)
D1787MO
Neoadjuvant durvalumab (D) + chemotherapy (CT) followed
by either surgery (Sx) and adjuvant D or CRT and
consolidation D in patients (pts) with resectable or borderline
resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the
phase 2 MDT-BRIDGE study
LBA65
Perioperative Pembrolizumab in Early-Stage Non–Small-Cell
Lung Cancer (NSCLC): 5-Year Follow-Up From KEYNOTE-671
LBA67
CCTG BR.31: Adjuvant durvalumab (D) in resected
non-small-cell lung cancer (NSCLC): final overall survival (OS)
and minimal residual disease (MRD) analyses.
LBA5
Association of radiomic features ± on-treatment ctDNA
detection with treatment outcomes in patients with
resectable NSCLC: exploratory analyses from AEGEAN
LBA70
ESMO 2025
TEMPRANO
PULMÓN
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
LBA5 - Sacituzumab tirumotecan (sac-TMT) vs
platinum-based chemotherapy in EGFR-mutated
(EGFRm) non-small cell lung cancer (NSCLC) following
progression on EGFR-TKIs: results from the randomized,
multi-center phase III OptiTROP-Lung04 stu
LBA5
Phase III study of ivonescimab plus chemotherapy versus
tislelizumab plus chemotherapy as first-line treatment for
advanced squamous non-small cell lung cancer
(HARMONi-6)
LBA4
Association between patient-reported outcomes (PROs) and
overall survival (OS) in aNSCLC patients treated with first-line
(1L) cemiplimab-based therapy
1862P
NorthStar: A phase II randomized study of osimertinib (OSI)
with or without local consolidative therapy (LCT) for
metastatic EGFR-mutant non-small cell lung cancer (NSCLC)
LBA72
Final overall survival (OS) and safety analysis of the phase III
ALEX study of alectinib vs crizotinib in patients with
previously untreated, advanced ALK-positive (ALK+)
non-small cell lung cancer (NSCLC)
LBA73
ESMO 2025
LOCALMENTE AVANZADO Y METASTÁSICO
PULMÓN
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Sevabertinib (BAY 2927088) in advanced HER2-mutant
non-small cell lung cancer (NSCLC): Results from the
SOHO-01 study
LBA75
FLAURA2: Exploratory overall survival (OS) analysis in
patients (pts) with poorer prognostic factors treated with
osimertinib (osi) ± platinum-pemetrexed chemotherapy
(CTx) as first-line (1L) treatment (tx) for EGFR-mutated
(EGFRm) advanced NSCLC Speakers
LBA77
Zongertinib as first-line treatment in patients with advanced
HER2-mutant NSCLC: Beamion LUNG 1
LBA74
Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT
bispecific antibody, for checkpoint inhibitor (CPI)-naïve
metastatic non-small cell lung cancer (mNSCLC):
ARTEMIDE-01
1853MO
Detailed safety analysis of DeLLphi-304: The first phase III
study to evaluate tarlatamab versus chemotherapy for
previously treated small cell lung cancer
LBA100
ESMO 2025
LOCALMENTE AVANZADO Y METASTÁSICO
PULMÓN
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Molecular residual disease (MRD) analysis from the LAURA
study of osimertinib (osi) in unresectable (UR) stage III
EGFR-mutated (EGFRm) NSCLC
1817MO
Activity of zipalertinib against active central nervous
system (CNS) metastases in patients with non-small cell
lung cancer (NSCLC) harboring EGFR exon 20 insertion
(ex20ins)/other uncommon mutations
1847MO
Phase II study of firmonertinib in patients with previously
treated advanced/metastatic non-small cell lung cancer
(mNSCLC) with EGFR exon 20 insertion (ex20ins)
mutations
1848MO
SAVANNAH: Safety and tolerability of osimertinib (osi) +
savolitinib (savo) in EGFRm advanced NSCLC with MET
overexpression and/or amplification (OverExp/Amp) following
disease progression on osi
1955P
ctDNA analysis in phase III SACHI trial: Savolitinib (savo) plus
osimertinib (osi) versus chemotherapy (chemo) in
MET-amplified (METamp) advanced NSCLC after disease
progression (PD) on EGFR tyrosine kinase inhibitor (TKI)
1954P
Osimertinib then chemotherapy in EGFR-mutated lung
cancer with osimertinib third-line rechallenge
(OCELOT-cohort A interim analysis)
1956P
Osimertinib rechallenge after relapse following adjuvant
osimertinib: A single center retrospective analysis of
ADAURA
2049eP
ESMO 2025
LOCALMENTE AVANZADO Y METASTÁSICO
PULMÓN
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Primary results from a randomized phase 2 trial of BNT111
in combination with cemiplimab with calibrator
monotherapy arms in anti-PD-(L)1 relapsed/refractory
melanoma
1605MO
Combined percutaneous hepatic perfusion with
ipilimumab plus nivolumab in metastatic uveal melanoma
(CHOPIN): A single-center, open-label, randomized, phase
II study
LBA59
Predicting real-world overall survival in advanced melanoma
using machine learning
1632P
Randomization to adjuvant nivolumab or ipilimumab +
nivolumab based on pathological response to a single dose of
neoadjuvant nivolumab in stage III melanoma
1604O
ESMO 2025
MELANOMA
PIEL
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Enucleation prevention and vision preservation in
primary uveal melanoma (UM): Preliminary results from a
phase II study of neoadjuvant darovasertib
1602O
3-year survival with neoadjuvant-adjuvant pembrolizumab
from SWOG S1801
1601O
Two-year clinical update and first biomarker analyses of the
phase III NADINA trial comparing neoadjuvant nivolumab
plus ipilimumab versus adjuvant nivolumab in resectable
stage III melanoma
LBA57
Efficacy and safety of IMA203, a PRAME-directed T-cell
receptor (TCR) T-cell therapy, in patients with previously
treated advanced or metastatic uveal melanoma from a
phase I trial
1600O
ESMO 2025
MELANOMA
PIEL
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Adjuvant cemiplimab for high-risk cutaneous squamous
cell carcinoma: Evaluating dosing intervals in a phase III
trial
1660P
Analysis of second primary cutaneous squamous cell
carcinoma (CSCC) tumors (SPTs) reported during the
C-POST trial, a randomized phase 3 study of adjuvant
cemiplimab vs placebo (pbo) for high-risk CSCC
1603MO
CemiplimAb-rwlc survivorship and epidemiology (CASE): A
prospective, non-interventional study of the safety and
effectiveness of cemiplimab in immunocompromised /
immunosuppressed (IC/IS) patients with advanced cutaneous
squamous cell carcinoma (CSCC) at 2 years’ follow-up
1666P
Clinical outcomes and PD-L1 expression analyses from a trial
of mRNA-4359 plus pembrolizumab in checkpoint
inhibitor-resistant/refractory (CPI-R/R) melanoma
1515MO
EVX-01, a personalized cancer vaccine, induces potent T cell
responses and durable disease control in advanced
melanoma: 2-year follow-up
1516MO
ESMO 2025
CARCINOMA ESCAMOCELULAR
PIEL
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
3-year survival with neoadjuvant-adjuvant
pembrolizumab from SWOG S1801
1601O
Two-year clinical update and first biomarker analyses of the
phase III NADINA trial comparing neoadjuvant nivolumab
plus ipilimumab versus adjuvant nivolumab in resectable
stage III melanoma
LBA57
Rescuing cancer immunotherapy with plasma exchange in
melanoma (the ReCIPE-M1 study)
1518MO
Randomization to adjuvant nivolumab or ipilimumab +
nivolumab based on pathological response to a single dose
of neoadjuvant nivolumab in stage III melanoma
1604O
ESMO 2025
CARCINOMA ESCAMOCELULAR
PIEL
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50
mg/m2 in combination with darolutamide + ADT in
patients with mHSPC: Results from the randomised
phase III ARASAFE trial
LBA92
First interim efficacy analysis of the phase I/II
PETRANHA trial of saruparib + androgen receptor
pathway inhibitors (ARPI) in patients (pts) with
metastatic prostate cancer (mPC)
2384MO
Patient (pt) reported outcomes (PROs) from AMPLITUDE, a
randomized placebo-controlled phase III trial of niraparib
(NIRA) and abiraterone acetate (AA) plus prednisone (P) in
metastatic hormone-sensitive prostate cancer (mHSPC) with
homologous recombination repair mutations (HRRm)
LBA91
EMBARK: Overall survival with enzalutamide in biochemically
recurrent prostate cancer
LBA87
Randomised phase III trial of androgen deprivation therapy
(ADT) with radiation therapy with or without enzalutamide
for high risk, clinically localised prostate cancer: ENZARAD
(ANZUP 1303)
LBA86
ESMO 2025
PRÓSTATA
GENITOURINARIO
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Prospective randomized phase II trial of
177Lutetium-PSMA therapy neoadjuvant to stereotactic
ablative radiotherapy for recurrent oligo-metastatic
hormone-sensitive prostate cancer (LUNAR
NCT05496959)
LBA90
A randomised trial of continuing or de-escalating bone
modifying agents (BMA) after more than 2 years of
treatment in patients with bone metastases from
breast or castration-resistant prostate cancer:
REaCT-Hold BMA
2800O
Final results from PRESTO: A phase III open-label study of
combined androgen blockade in patients (pts) with high-risk
biochemically relapsed prostate cancer (BRPC) (AFT-19)
LBA88
Efficacy and safety of 177Lu-PSMA-617 (LuPSMA) in elderly
patients (pts) with metastatic castration-resistant prostate
cancer (mCRPC)
2409P
177Lu-PSMA-617 in oligometastatic hormone sensitive
prostate cancer (BULLSEYE)
2387P
ESMO 2025
PRÓSTATA
GENITOURINARIO
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Disitamab vedotin (DV) plus toripalimab (T) versus
chemotherapy (C) in first-line (1L) locally advanced or
metastatic urothelial carcinoma (la/mUC) with
HER2-expression
LBA7
Perioperative (periop) enfortumab vedotin (EV) plus
pembrolizumab (pembro) in participants (pts) with
muscle-invasive bladder cancer (MIBC) who are
cisplatin-ineligible: The phase 3 KEYNOTE-905 study
LBA2
IMvigor011: a Phase 3 trial of circulating tumour
(ct)DNA-guided adjuvant atezolizumab vs placebo in
muscle-invasive bladder cancer
LBA8
Adjuvant nivolumab vs placebo for high-risk muscle-invasive
urothelial carcinoma: 5-year efficacy and ctDNA results from
CheckMate 274
3068O
ALBAN: A phase 3, randomized, open-label, international
study of intravenous (iv) atezolizumab and intravesical
Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG-naïve
high-risk, non-muscle-invasive bladder cancer (NMIBC)
LBA107
Durvalumab (D) in combination with Bacillus
Calmette-Guérin (BCG) for BCG-naïve, high-risk
non-muscle-invasive bladder cancer (NMIBC): Final analysis
of the phase III, open-label, randomised POTOMAC trial
LBA108
ESMO 2025
UROTELIAL
GENITOURINARIO
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
First-line pembrolizumab-based regimens for
advanced clear cell renal cell carcinoma:
KEYMAKER-U03 substudy 03A
LBA96
LenCabo: A randomized phase II multicenter trial of
lenvatinib plus everolimus (len/eve) versus (vs)
cabozantinib (cabo) in patients (pts) with metastatic
clear cell RCC (ccRCC) that progressed on PD-1
immune checkpoint inhibition (ICI)
LBA94
Final efficacy data and biomarker análisis from the clear cell
cohort of CALYPSO
2605MO
First results from RAMPART: An international pase 3
randomised-controlled trial of adjuvant durvalumab
monotherapy or combined with tremelimumab for resected
primary rena lcell carcinoma (RCC) led by MRCCTU at UCL
LBA93
ESMO 2025
RENAL
GENITOURINARIO
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Association o fcirculating kidney injury
molecule-1(KIM-1) levels with clinical outcomes in
advanced renal cell carcinoma (aRCC): Retrospective
análisis of COSMIC-313
2594MO
Exploratory analysis of chromophobe renal cell
carcinoma in the SUNNIFORECAST trial comparing
Ipilimumab plus Nivolumab vs standard of care as
first-line treatment
2595MO
Neoadjuvant immunotherapy in locally advanced clear cell
renal cell carcinoma at risk fo recurrence or distant
metastases: The randomized pase II NESCIO trial.
LBA95
Final analysis of lenvatinib+ pembrolizumab (L+P) vs
sunitinib (S) in patients with advanced renal cell carcinoma
(aRCC) with or without bone metastases in CLEAR
2603P
ESMO 2025
RENAL
GENITOURINARIO
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
SKYSCRAPER-07: A phase III, randomised study of
atezolizumab (atezo) with or without tiragolumab (tira) in
patients (pts) with unresectable esophageal squamous
cell carcinoma (ESCC) that has not progressed following
definitive concurrent chemoradiotherapy (dCRT)
2094O
Lenvatinib plus Pembrolizumab and Chemotherapy vs
Pembrolizumab and Chemotherapy in Untreated
Metastatic Esophageal Squamous Cell Carcinoma: The
Randomized Phase 3 LEAP-014 Study
LBA79
Final overall survival (OS) and the association of pathological
outcomes with event-free survival (EFS) in MATTERHORN: A
randomised, phase III study of durvalumab (D) plus
5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in
resectable gastric / gastroesophageal junction (G / GEJ)
adenocarcinoma
LBA81
ESMO 2025
ESOFAGOGÁSTRICO
GASTROINTESTINAL
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
ESMO 2025
ESOFAGOGÁSTRICO
GASTROINTESTINAL
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Regorafenib plus nivolumab vs investigator’s choice of
chemotherapy in previouslytreated gastric or
gastroesophageal cancer: INTEGRATE IIb, a randomized
phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU,
TCOG/NHRI] study
LBA80
KN026 in combination with chemotherapy for previously
treated HER2 positive gastric or gastroesophageal
carcinomas (GC/GEJC): Interim analysis of KC-WISE
LBA78
RC118 (CLDN18.2-targeted ADC) combined with PD-1
blockade or RC148 (PD1/VEGF bispecific antibody) for locally
advanced or metastatic gastric/gastroesophageal junction
adenocarcinoma (la/m G/GEJA)
LBA83
Bemarituzumab (BEMA) plus chemotherapy for
advanced or metastatic FGFR2b-overexpressing gastric
or gastroesophageal junction cancer (G/GEJC):
FORTITUDE-101 phase 3 study results
LBA10
ESMO 2025
HEPATOBILIOPANCREÁTICO
GASTROINTESTINAL
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Durvalumab (D) plus tremelimumab (T) in advanced biliary
tract carcinoma (BTC) patients (Pts) after failure of
platinum-based chemotherapy (CTx): Final results of the
IMMUNOBIL GERCOR D18-1 PRODIGE-57 phase II triaL
80MO
Results of a randomized phase III trial of short-course versus
long-course pre-operative chemotherapy for stage I-III
pancreatic ductal adenocarcinoma (PDAC)
LBA85
Efficacy and safety of GFH375 monotherapy in previously
treated advanced KRAS G12D-mutant pancreatic ductal
adenocarcinoma (PDAC)
LBA84
VIRAGE trial: Randomized phase IIb, open-label, study
of nab-paclitaxel and gemcitabine with/without
intravenous VCN-01 in patients with metastatic
pancreatic cancer (mPDAC)
2216MO
ESMO 2025
HEPATOBILIOPANCREÁTICO
GASTROINTESTINAL
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Management of asymptomatic sporadic nonfunctioning
pancreatic neuroendocrine neoplasms ≤2 cm: A
prospective international observational multicentric cohort
study (ASPEN study)
LBA36
Single-agent divarasib experience in patients with KRAS
G12C-positive pancreatic adenocarcinoma (panc),
cholangiocarcinoma (cholangio), and other solid tumor
927MO
Liver resection versus continued atezolizumab plus
bevacizumab (atezo/bev) in locally advanced hepatocellular
carcinoma (HCC) after atezo/bev treatment (TALENTop): A
multicenter, open-label, randomized phase III trial
1469MO
IKF-035/ABC-HCC: A phase IIIb, randomized,
multicenter, open-label trial of atezolizumab plus
bevacizumab versus transarterial chemoembolization
(TACE) in intermediate-stage hepatocellular carcinoma
LBA51
ESMO 2025
COLORRECTAL
GASTROINTESTINAL
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Zanzalintinib plus atezolizumab (zanza + atezo) vs
regorafenib (rego) in patients (pts) with previously treated
metastatic colorectal cancer (mCRC): Primary overall
survival (OS) analysis from the randomized, open-label,
phase 3 STELLAR-303 study
LBA30
Post-surgical liquid biopsy-guided treatment of stage III and
high-risk stage II colon cancer patients: final results of the
PEGASUS trial
723O
Comparison of outcomes in clinical trials of locally advanced
dMMR colon cancer: FOxTROT and NICHE-2
724O
Trastuzumab deruxtecan (T-DXd) in patients (pts) with
HER2-positive (HER2+) metastatic colorectal cancer
(mCRC): final analysis of DESTINY-CRC02, a randomized,
phase 2 trial
737MO
ESMO 2025
COLORRECTAL
GASTROINTESTINAL
ESMO 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Nivolumab plus ipilimumab vs nivolumab monotherapy for
microsatellite instability-high/mismatch repair-deficient
(MSI-H/dMMR) metastatic colorectal cancer (mCRC): new
results from CheckMate 8HW
LBA29
Circulating tumor (ct) DNA analysis of BRAF V600E
dynamics and changes in genomic landscape in patients
(pts) with first-line (1L) BRAF V600E-mutant metastatic
colorectal cancer (mCRC) treated in BREAKWATER
729O
Panitumumab retreatment followed by regorafenib versus
the reverse sequence in chemorefractory metastatic
colorectal cancer patients with RAS and BRAF wild-type
circulating tumor DNA (ctDNA): Final results of the
randomized PARERE trial by GONO
LBA32